Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-Gastric/Gastroesophageal Junction Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Not Yet RecruitingNCT07829757
What this trial is testing

Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc. 50
Testing effectiveness (Phase 2)Ended earlyNCT04278144
What this trial is testing

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

Who this might be right for
HER2-positive Solid TumorsHER2-positive Breast CancerHER2-positive Colorectal Cancer+2 more
Bolt Biotherapeutics, Inc. 175
Large-scale testing (Phase 3)Active Not RecruitingNCT04704934
What this trial is testing

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

Who this might be right for
Gastric Cancer, AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Daiichi Sankyo 490
Early research (Phase 1)WithdrawnNCT06341647
What this trial is testing

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

Who this might be right for
Breast CancerGastric CancerGastroesophageal Junction Adenocarcinoma
GC Cell Corporation
Testing effectiveness (Phase 2)Looking for participantsNCT05894824
What this trial is testing

T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Who this might be right for
Gastric CancerGastroesophageal Junction (GEJ) Cancer
Yonsei University 58
Large-scale testing (Phase 3)Active Not RecruitingNCT03504397
What this trial is testing

Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Study completedNCT03925974
What this trial is testing

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Who this might be right for
Gastric/Gastroesophageal Junction Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 45
Early research (Phase 1)Study completedNCT04513223
What this trial is testing

SHR-A1811 in Patients With Selected HER2 Expressing Tumors

Who this might be right for
Gastric CancerColorectal Cancer
Jiangsu HengRui Medicine Co., Ltd. 101
Not applicableStudy completedNCT06585501
What this trial is testing

Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Daiichi Sankyo 805
Testing effectiveness (Phase 2)Ended earlyNCT04933227
What this trial is testing

Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Who this might be right for
Stomach NeoplasmsGastric CancerGastroesophageal Junction Adenocarcinoma
Hoffmann-La Roche 29
Large-scale testing (Phase 3)Active Not RecruitingNCT05002127
What this trial is testing

Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
ALX Oncology Inc. 127
Early research (Phase 1)Ended earlyNCT06714617
What this trial is testing

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Who this might be right for
Breast Cancer Stage IIIHER2-positive Metastatic Breast CancerUnresectable Breast Carcinoma+11 more
SystImmune Inc. 3
Early research (Phase 1)UnknownNCT03847168
What this trial is testing

KN026 in Patients With HER2 Expressing Breast Cancer and Gastric Cancer

Who this might be right for
Breast CancerGastric/Gastroesophageal Junction Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 22
Large-scale testing (Phase 3)Active Not RecruitingNCT03653507
What this trial is testing

Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Early research (Phase 1)Looking for participantsNCT06293898
What this trial is testing

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Who this might be right for
Endometrial CancerCervical CancerOvarian Cancer+7 more
SystImmune Inc. 280
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07685704
What this trial is testing

Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
Zhifeng Zhao, PhD 46
Testing effectiveness (Phase 2)Study completedNCT02689284
What this trial is testing

Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric CancerStomach CancerEsophageal Cancer
MacroGenics 95
Testing effectiveness (Phase 2)UnknownNCT03817411
What this trial is testing

Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer

Who this might be right for
Gastric Cancer
Taizhou EOC Pharma Co., Ltd. 90
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07490990
What this trial is testing

Disitamab Vedotin Combined With Sintilimab and Multimodal Radiotherapy for HER2-Positive Advanced Gastric Cancer After Second-Line Treatment Failure: A Prospective, Single-Arm Phase II Clinical Trial

Who this might be right for
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
West China Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06385873
What this trial is testing

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Who this might be right for
Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital with Nanjing Medical University 32
Next Page
565
507